ObjectivesTo determine the impact of intimate partner violence on women’s mental and physical health over a 16 year period and across three generations.ParticipantsParticipants were from the Australian Longitudinal study on Women’s Health, a broadly representative national sample of women comprised of three birth cohorts 1973–78, 1946–51 and 1921–26 who were randomly selected from the Australian Medicare (i.e. national health insurer) database in 1996 to participate in the longitudinal health and wellbeing survey. Since baseline, six waves of survey data have been collected. Women from each cohort who had returned all six surveys and had a baseline measure (Survey 1) for intimate partner violence were eligible for the current study.Main outcome measuresThe main outcome of interest was women’s physical and mental health, measured using the Medical Outcome Study Short-Form (SF-36). The experience of intimate partner violence was measured using the survey item ‘Have you ever been in a violent relationship with a partner/spouse?’ Sociodemographic information was also collected.ResultsFor all cohorts, women who had lived with intimate partner violence were more likely to report poorer mental health, physical function and general health, and higher levels of bodily pain. Some generational differences existed. Younger women showed a reduction in health associated with the onset of intimate partner violence, which was not apparent for women in the older two groups. In addition, the physical health differences between women born 1921–26 who had and had not experienced intimate partner violence tapered off overtime, whereas these differences remained constant for women born 1973–78 and 1946–51.ConclusionsDespite generational differences, intimate partner violence adversely impacted on mental and physical health over the 16 year study period and across generations.

No abstract

COVID-19 has been shown to present with varied clinical course, necessitating a need for more specific diagnostic tools that could identify severe cases and predict outcomes during COVID-19 infection. Recent evidence has shown an expanded potential role for calprotectin, both as a diagnostic tool and also as a tool in stratifying COVID-19 patients in terms of severity. Therefore, this systematic review and meta-analysis aims to evaluate the levels of calprotectin in severe and non-severe COVID-19 and also identify the implication of raised calprotectin levels. MEDLINE, EMBASE, The Cochrane Library, Web of science and MedRxiv were searched. Meta-analysis was done to compare the serum/fecal levels of calprotectin between severe and non-severe COVID-19 infections. A total of ten studies included in the review (eight had quantitative data while two were qualitative). A pooled analysis of the eight studies from 613 patients who were RT-PCR positive for COVID-19 (average age = 55 years; 52% males) showed an overall estimate as 1.34 (95%CI: 0.77, 1.91). In conclusion, calprotectin levels have been demonstrated to be significantly elevated in COVID-19 patients who develop the severe form of the disease, and it also has prognostic importance.

Long‐term sequelae conditions of COVID‐19 at least 2‐year following SARS‐CoV‐2 infection are unclear and little is known about their prevalence, longitudinal trajectory, and potential risk factors. Therefore, we conducted a comprehensive meta‐analysis of survivors' health‐related consequences and sequelae at 2‐year following SARS‐CoV‐2 infection. PubMed/MEDLINE, CENTRAL, and EMBASE were systematically searched up to February 10, 2023. A systematic review and meta‐analysis were performed to calculate the pooled effect size, expressed as event rate (ER) with corresponding 95% confidence interval (CI) of each outcome. Twelve studies involving 1 289 044 participants from 11 countries were included. A total of 41.7% of COVID‐19 survivors experienced at least one unresolved symptom and 14.1% were unable to return to work at 2‐year after SARS‐CoV‐2 infection. The most frequent symptoms and investigated findings at 2‐year after SARS‐CoV‐2 infection were fatigue (27.4%; 95% CI 17%–40.9%), sleep difficulties (25.1%; 95% CI 22.4%–27.9%), impaired diffusion capacity for carbon monoxide (24.6%; 95% CI 10.8%–46.9%), hair loss (10.2%; 95% CI 7.3%–14.2%), and dyspnea (10.1%; 95% CI 4.3%–21.9%). Individuals with severe infection suffered more from anxiety (OR = 1.69, 95% CI 1.17–2.44) and had more impairments in forced vital capacity (OR = 9.70, 95% CI 1.94–48.41), total lung capacity (OR = 3.51, 95% CI 1.77–6.99), and residual volume (OR = 3.35, 95% CI 1.85–6.07) after recovery. Existing evidence suggest that participants with a higher risk of long‐term sequelae were older, mostly female, had pre‐existing medical comorbidities, with more severe status, underwent corticosteroid therapy, and higher inflammation at acute infection. Our findings suggest that 2‐year after recovery from SARS‐CoV‐2 infection, 41.7% of survivors still suffer from either neurological, physical, and psychological sequela. These findings indicate that there is an urgent need to preclude persistent or emerging long‐term sequelae and provide intervention strategies to reduce the risk of long COVID.

Diet quality indices (DQIs) can be useful predictors of diet–disease relationships, including non-communicable disease (NCD) multimorbidity. We aimed to investigate whether overall diet quality (DQ) predicted NCD, multimorbidity, and all-cause mortality. Women from the 1945–51 cohort of the Australia Longitudinal Study on Women’s Health (ALSWH) were included if they: responded to S3 in 2001 and at least one survey between 2004 (S4) and 2016 (S8), and had no NCD history and complete dietary data at S3. DQ was summarized by the Healthy Eating Index for Australian Adults-2013 (HEIFA-2013), Mediterranean Diet Score (MDS), and Alternative Healthy Eating Index-2010 (AHEI-2010). Outcomes included each NCD (diabetes mellitus (DM), coronary heart disease (CHD), hypertension (HT), asthma, cancer (except skin cancer), depression and/or anxiety) independently, multimorbidity, and all-cause mortality. Repeated multivariate logistic regressions were used to test associations between DQIs and NCD outcomes across the 15 years of follow-up. The mean (±sd) of DQIs of participants (n = 5350) were 57.15 ± 8.16 (HEIFA-2013); 4.35 ± 1.75 (MDS), and 56.01 ± 10.32 (AHEI-2010). Multivariate regressions indicated that women reporting the highest quintile of AHEI-2010 had lower odds of DM (42–56% (S5–S8)), HT (26% (S8)), asthma (35–37% (S7, S8)), and multimorbidity (30–35% (S7, S8)). The highest quintile of HEIFA-2013 and MDS had lower odds of HT (26–35% (S7, S8); 24–27% (S6–S8), respectively) and depression and/or anxiety (30% (S6): 30–34% (S7, S8)). Our findings support evidence that DQ is an important predictor of some NCDs and a target for prevention in middle-aged women.

This study examines differences in uptake of the Medicare items rolled out in 2006 under the 'Better Access Scheme' (BAS) between rural and non-rural Australian women. It compares differences in women's uptake of the BAS services by area of residence (ARIA+) across time using the Australian Longitudinal Study of Women's Health (ALSWH) survey data linked to Medicare data. Women aged 28-33 years at the time the BAS was introduced that responded to the self-reported question on depression/anxiety and consented to linkage of their survey data with Medicare data (n=4,316). Participants were grouped by ARIA+ according to BAS use, diagnoses of anxiety/depression but no BAS use and other eligible women. Across all areas, women born 1973-1978 with a self-reported diagnosis of depression/anxiety or having treatment under the BAS had a significantly lower mean mental health score compared to other women. Significantly more women living in non-rural areas had used at least one service provided under the BAS initiative compared to women in outer regional, inner regional or remotes areas (21% versus 18% versus 13% versus 7%, respectively), and across all areas, 12% of women reported having a diagnosis of depression/anxiety but not been treated under the BAS. While there is a gradual uptake of the new BAS services, a large percentage of women who have a diagnosis of depression/anxiety have not been treated under the BAS. The data suggest that women in urban areas have been better able to take up the services compared to non-urban women.

Objective: To quantify women's uptake of Medicare Benefits Schedule mental health items, compare characteristics of women by mental health service use, and investigate the impact on Medicare costs. Design, setting and participants: Analysis of linked survey data and Medicare records (November 2006 – December 2007) of 14 911 consenting participants of the Australian Longitudinal Study on Women's Health (ALSWH) across three birth cohorts (1921–1926 [“older cohort”], 1946–1951 [“mid‐age cohort”], and 1973–1978 [“younger cohort”]). Main outcome measures: Uptake of mental health items; 36‐Item Short Form Health Survey (SF‐36) Mental Health Index scores from ALSWH surveys; and patient (out‐of‐pocket) and benefit (government) costs from Medicare data. Results: A large proportion of women who reported mental health problems made no mental health claims (on the most recent survey, 88%, 90% and 99% of the younger, mid‐age and older cohorts, respectively). Socioeconomically disadvantaged women were less likely to use the services. SF‐36 Mental Health Index scores among women in the younger and mid‐age cohorts were lowest for women who had accessed mental health items or self‐reported a recent mental health condition. Mental health items are associated with higher costs to women and government. Conclusion: Although there has been rapid uptake of mental health items, uptake by women with mental health needs is low and there is potential socioeconomic inequity.

No abstract